(NSCLC) patients who have tumor progression after having previously
benefited from EGFR inhibitors.
-- Presented comprehensive phase 1 data for XL880 in June, and published
abstracts on phase 1 data for XL184, XL647 and XL880.
-- Reported phase 2 proof-of-concept data for XL647 as first-line therapy
for NSCLC in September.
-- Presented phase 1 data for second-generation MET inhibitor XL184,
selective PI3K inhibitor XL147 and dual PI3K/mTOR inhibitor XL765, and
phase 2 data for XL880 in papillary renal cell carcinoma and phase 2
data for XL647 in NSCLC in October.
-- Presented encouraging phase 1 data for XL019, our selective inhibitor
of JAK2, in December.
-- Filed investigational new drug applications for four compounds: XL418
(January), XL147 (March), XL765 (April) and XL019 (May).
-- Advanced new development candidates into preclinical development,
including XL139 (Hedgehog antagonist), XL888 (HSP90 inhibitor) and
XL652 (LXR modulator).
-- Held our Third Annual Exelixis Research and Development Day in
-- Retained rights to develop and commercialize XL647 after
GlaxoSmithKline declined to exercise its option to further develop and
commercialize the compound.
-- Received notice of GlaxoSmithKline's selection of XL880 for further
development and commercialization. We expect the XL880 program to be
transferred to GlaxoSmithKline in the first quarter of 2008.
-- Presented phase 2 data for XL784 in November indicating that XL784 did
not meet its primary endpoint, and as expected, GSK chose not to
exercise its option to further develop XL784. Based on encouraging
data from a subgroup analysis, the compound may nevertheless have
potential to benefit patients with diabet
|SOURCE Exelixis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved